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Human hotspot TERT promoter (TERTp) mutations have been reported in a wide range of tumours. Several studies have shown
that TERTp mutations are associated with clinicopathological features; in some instances, TERTp mutations were considered
as biomarkers of poor prognosis. The rs2853669 SNP, located in the TERT promoter region, was reported to modulate the
increased TERT expression levels induced by the recurrent somatic mutations. In this study we aimed to determine the fre-
quency and prognostic value of TERTp mutations and TERT rs2853669 SNP in 504 gliomas from Portuguese and Brazilian
patients. TERTp mutations were detected in 47.8% of gliomas (216/452). Glioblastomas (GBM) exhibited the highest frequency
of TERTp mutations (66.9%); in this glioma subtype, we found a significant association between TERTp mutations and poor
prognosis, regardless of the population. Moreover, in a multivariate analysis, TERTp mutations were the only independent
prognostic factor. Our data also showed that the poor prognosis conferred by TERTp mutations was restricted to GBM patients
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carrying the rs2853669 A allele and not in those carrying the G allele. In conclusion, the presence of TERTp mutations was
associated with worse prognosis in GBM patients, although such association depended on the status of the rs2853669 SNP.
The status of the rs2853669 SNP should be taken in consideration when assessing the prognostic value of TERTp mutations
in GBM patients. TERTp mutations and the rs2853669 SNP can be used in the future as biomarkers of glioma prognosis.
Gliomas are the most common malignant primary brain
tumour in adults.1,2 According to the WHO classiﬁcation,
astrocytoma is the most frequent histological subtype of gli-
oma, followed by oligodendroglioma and oligoastrocytoma.1
Gliomas can be divided in 4 malignancy grades, from WHO
grade I to WHO grade IV. Pilocytic astrocytomas (WHO
grade I) are considered benign tumours and occur more
commonly in children. Diffuse astrocytomas (WHO grade II)
arise in young adults and, despite being low-grade gliomas,
frequently evolve to higher grade malignancies, such as ana-
plastic astrocytomas (WHO grade III) and glioblastomas
(GBM; WHO grade IV).1 Oligodendrogliomas and oligoastro-
cytomas can be classiﬁed as low-grade or high-grade/anaplas-
tic tumours (WHO grade II and III, respectively). GBM is
not only the most malignant, but also the most frequent
brain tumour. The current gold-standard therapy for GBM
patients combines temozolomide with radiotherapy, with an
overall survival of about 15 months.3 Therefore, the progno-
sis of GBM patients is still dismal, highlighting the need for
identifying and consolidating biomarkers that help in the
management of the patients.
Achieving cancer cell immortalization depends on the
ability to circumvent the telomere erosion sensing mecha-
nisms and evade senescence or cell death. Two major path-
ways are used by cancer cells for telomere maintenance:
reactivation of telomerase—a ribonucleoprotein protein con-
sisting of molecules each of human telomerase reverse tran-
scriptase (TERT) and telomerase RNA (TERC) —that
elongates telomeres by adding 50-TTAGGG-30 tandem repeats
to the tips of the chromosomes, or engagement in a nontelo-
merase dependent mechanism, the “alternative lengthening of
telomeres” (ALT).4,5 Reactivation of telomerase is reported in
up to 90% of human cancers,6 although the underlying
mechanisms have only recently started to be revealed.
Two seminal papers reported a high frequency of TERT
promoter (TERTp) mutations in familial and sporadic forms
of melanoma.7,8 The mutations were present in the promoter
region of the TERT gene and largely clustered in two
hotspots positions, located upstream of the ATG site, at
positions 2146 bp (c.2146:G>A) and 2124 bp
(c.2124:G>A).8 TERTp mutations generate a new consensus
binding site for ETS/TCFs transcription factors (CCGGAA)
and lead to a 2- to 4-fold increase of the TERT promoter
activity.7,8 Recently, it was also shown that GABP is the criti-
cal ETS transcription factor activating TERT expression in the
context of these highly recurrent promoter mutations.9 We
and others extended the search to other tumour models and
reported the presence of these recurrent somatic mutations in
tumours of the central nervous system (CNS), bladder, liver,
thyroid (follicular cell-derived tumours), skin and tumours ori-
ginated in tissues with low rates of self-renewal.10–14 Gliomas
are among the tumours harbouring the highest frequency of
TERTp mutations10,13,15–21; in GBM, such frequency can be as
high as 84% but elevated frequencies are also found in low
and high-grade oligodendroglial tumours.6,10,13
Recent studies reported that the rs2853669 A>G single
nucleotide polymorphism (SNP), located 2245 bp upstream
of the TERT gene ATG site, modulates the increased TERT
mRNA expression levels induced by the recurrent TERTp
somatic mutations.22 The less common G allele reverts the
biological effect of TERTp mutations and also modiﬁes the
outcome in patients with bladder cancer and gliomas.23–25
In this study we investigated the frequency and prognostic
value of TERTp mutations and TERT rs2853669 SNP in glio-
mas. The analysis was performed in two series of gliomas—
one composed of Portuguese patients (n5 298) and another
composed of Brazilian patients (n5 206) —as a whole or
separately.
Material and Methods
Tumor samples
Representative formalin-ﬁxed parafﬁn-embedded (FFPE)
samples from 504 gliomas were retrieved from the pathology
archives of Portuguese institutions (Centro Hospitalar S~ao
Jo~ao, Hospital Pedro Hispano and Hospital de Braga) and
Brazilian hospitals (Hospital de Ca^ncer de Barretos and
What’s new?
Cancer cells avoid senescence in part by reactivating telomerase (TERT), a ribonucleoprotein that replenishes shortening telo-
meres. Here, the authors discover a positive association between TERT promoter mutations and unfavorable prognosis in glio-
blastoma patients from Portuguese and Brazilian origin. This association was only observed in patients with a specific allelic
background (AA) in a TERT polymorphism (rs2853669) recently linked to enhanced TERT mRNA levels. The authors recommend
considering the allelic status of rs2853669 when assessing the prognostic value of TERT promoter mutations in glioblastoma
patients.
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Preto). All tumours were reviewed and classiﬁed according to
the WHO classiﬁcation of CNS tumours.1 Of the 504 sam-
ples, 298 were from Portugal and 206 were from Brazil. Sup-
porting Information Table S1 summarizes the distribution of
samples per histotype in both series. The only major differ-
ence concerns the percentage of pilocytic astrocytomas, which
was higher in the Brazilian series than in the Portuguese
series. Part of the results reported in this study, in particular
the frequency of TERTp mutations in 118 gliomas, has been
previously published elsewhere.13
The information on gender, age at diagnosis, tumour loca-
tion, Karnofsky Performance Status and radio/chemotherapy
is summarized in Table 1. All the procedures described in
this study were in accordance with national and institutional
ethical standards and previously approved by Local Ethical
Review Committees.
Genotyping characterization
DNA from FFPE tissues was retrieved from 10 lm cuts, after
careful macrodissection of tumour area, ensuring the pres-
ence of >75% of neoplastic cells, as well as absence of necro-
sis and microvascular proliferation. DNA extraction of the
Portuguese and Brazilian samples was performed using the
Ultraprep Tissue DNA Kit (AHN Biotechnologie, Nordhau-
sen, Germany) and Qiagen’s QIAampVR DNA Micro Kit
(Qiagen, Venlo, The Netherlands), respectively, following the
manufacturer’s instructions. DNA was further quantiﬁed by
NanoDropVR 2000 (Thermo Scientiﬁc, Waltham) and stored
at 2208C until further genetic analysis.
The c.2146:G>A and c.2124:G>A hotspot TERTp
mutations were screened by PCR followed by direct
Sanger sequencing as previously described.13 PCR for
TERTp mutation analysis was performed with the primer pair
Fw: 50-CAGCGCTGCCTGAAACTC-30 and Rw: 50-
GTCCTGCCCCTTCACCTT-30 resulting in a PCR product of
235 bp, which contained the sites chr5.hg19:g.1295228C>T
and chr5.hg19:g.1295250C>T, corresponding to the
c.2124:G>A and c.2146:G>A mutations, respectively. PCR
ampliﬁcation of the genomic DNA (25–100 ng) was per-
formed using the Qiagen Multiplex PCR kit (Qiagen, Venlo,
The Netherlands) according to the manufacturer’s protocol,
using Q solution. Sequencing reactions were performed with
the ABI Prism BigDye Terminator Kit (Life Technologies,
Carlsbad) and the fragments were run in an ABI prism 3100
and 3500 xL Genetic Analyser (Life Technologies, Carlsbad).
The sequencing reaction was performed in forward direc-
tion. An independent PCR ampliﬁcation/sequencing, both in
a forward and reverse direction, was performed in positive
samples or samples that were inconclusive. For genotyping
the rs2853669 SNP, the electropherogram analysis of the
same 235 bp PCR product allowed the genotyping of
rs2853669 SNP. Additionally, in a subset of GBM (n5 85)
we also used the TaqMan SNP genotyping assay ID:
C___8773290_10 (Life Technologies, Carlsbad, USA). The
procedure was performed by real time PCR according to
manufacturer’s instructions in an ABI Prism 7500 Fast sys-
tem (Life Technologies, Carlsbad).
Statistical analysis
Statistical analysis was conducted with SPSS version 22.0
(IBM, Armonk). Fisher’s exact test and Student’s t test
(unpaired, two tailed) were used when appropriate. The
predictive value of TERTp mutations and other factors (age,
gender and Karnofsky Performance Status) were assessed
using univariate and multivariate logistic regression models.
Survival curves were plotted by the Kaplan-Meier method
with the log-rank statistics. Multivariate survival analysis was
performed using Cox regression. Results were considered
statistically signiﬁcant if p< 0.05.
Results
Altogether, we detected the presence of TERTp mutations in
216 out of 452 gliomas (47.8%). In 52 cases, the low quantity
or quality of DNA precluded the evaluation of TERTp muta-
tions. The most common mutation was the c.2124:G>A,
detected in 154 cases (71.3%), whereas the c.2146:G>A was
found in 62 cases (28.7%). TERTp mutations were more
frequently detected in glioblastoma (66.9%), followed by ana-
plastic oligodendroglioma (51.5%), grade II oligodendro-
glioma (46.3%), oligoastrocytoma (40.0%), diffuse
astrocytoma (15.2%), anaplastic astrocytoma (10.0%) and
pilocytic astrocytoma (7.2%; Supporting Information Table
S2). In 22 cases, we had access to the material from the pri-
mary tumour (initial surgery) and the recurrence. When
comparing primary vs. recurrence, all cases showed concord-
ant results regarding the presence of TERTp mutations, with
the exception of one anaplastic oligodendroglioma, in which
we detected the c.2124:G>A TERTp mutation in the recur-
rence but not in the primary tumour (Supporting Informa-
tion Table S3).
TERTp mutations in astrocytomas
TERTp mutations were detected in all astrocytoma subtypes,
with increasing frequencies along more malignant grades:
7.2% (4/55) in pilocytic astrocytomas (WHO grade I), 15.2%
(7/46) in diffuse astrocytomas (WHO grade II), 10.0% (1/10)
in anaplastic astrocytomas (WHO grade III) and 66.9% (141/
211) in GBM (WHO grade IV) (Supporting Information
Table S2). Among diffuse astrocytomas, TERTp mutations
were signiﬁcantly associated with older age at diagnosis (Sup-
porting Information Table S4). The low frequency of TERTp
mutations in grade I and III astrocytic tumours precluded
further statistical analyses.
TERTp mutations and GBM clinicopathological features
The highest frequency of TERTp mutations was detected in
GBM, with a similar frequency in Portuguese patients
(66.4%) and Brazilian patients (67.5%). When pooling Portu-
guese and Brazilian patients together, the presence of TERTp
T
um
or
M
ar
ke
rs
an
d
Si
gn
at
ur
es
416 TERTP mutations and SNP in GBM survival
Int. J. Cancer: 139, 414–423 (2016) VC 2016 UICC
Ta
b
le
1
.
C
li
n
ic
o
p
a
th
o
lo
g
ic
a
l
fe
a
tu
re
s
o
f
g
li
o
m
a
s
a
cr
o
ss
d
if
fe
re
n
t
h
is
to
lo
g
ic
a
l
su
b
ty
p
e
s
C
li
n
ic
a
l
fe
a
tu
re
s1
P
il
o
cy
ti
c
a
st
ro
cy
to
m
a
(n
5
6
7
)
D
if
fu
se
a
st
ro
cy
to
m
a
(n
5
5
0
)
A
n
a
p
la
st
ic
a
st
ro
cy
to
m
a
(n
5
1
0
)
G
li
o
b
la
st
o
m
a
(n
5
2
4
3
)
O
li
g
o
d
e
n
d
ro
-
g
li
o
m
a
(n
5
5
5
)
A
n
a
p
la
st
ic
o
li
g
o
d
e
n
d
ro
-
g
li
o
m
a
(n
5
6
7
)
O
li
g
o
a
st
ro
cy
-
to
m
a
(n
5
1
2
)
G
e
n
d
e
r
Fe
m
a
le
3
6
(5
3
.7
%
)
2
2
(4
5
.8
%
)
1
(1
0
.0
%
)
8
8
(3
7
.4
%
)
2
0
(3
7
.0
%
)
2
9
(4
3
.3
%
)
6
(5
0
.0
%
)
M
a
le
3
1
(4
6
.3
%
)
2
6
(5
4
.2
%
)
9
(9
0
.0
%
)
1
4
7
(6
2
.6
%
)
3
4
(6
3
.0
%
)
3
8
(5
6
.7
%
)
6
(5
0
.0
%
)
A
g
e
M
e
a
n
(r
a
n
g
e
)
1
4
(1
–
7
6
)
3
7
(4
–
7
8
)
4
5
(3
0
–
6
2
)
5
7
(1
8
–
8
2
)
4
2
(2
–
7
9
)
4
9
(9
–
8
1
)
3
5
(1
4
–
5
8
)
Tu
m
o
r
Lo
ca
ti
o
n
Fr
o
n
ta
l
3
(4
.5
%
)
1
1
(2
5
%
)
5
(5
5
.6
%
)
4
2
(1
8
.2
%
)
2
0
(4
2
.6
%
)
2
1
(3
5
.0
%
)
4
(3
6
.4
%
)
Te
m
p
o
ra
l
0
1
0
(2
2
.7
%
)
2
(2
2
.2
%
)
5
9
(2
5
.5
%
)
8
(1
7
.0
%
)
1
1
(1
8
.3
%
)
0
P
a
ri
e
ta
l
3
(4
.5
%
)
4
(9
.1
%
)
1
(1
1
.1
%
)
4
3
(1
8
.6
%
)
1
0
(2
1
.3
%
)
1
4
(2
3
.3
%
)
6
(5
4
.5
%
)
O
cc
ip
it
a
l
2
(3
%
)
3
(6
.8
%
)
0
1
3
(5
.6
%
)
0
3
(5
.0
%
)
0
M
u
lt
ip
le
0
6
(1
3
.6
%
)
1
(1
1
.1
%
)
6
5
(2
8
.1
%
)
6
(1
2
.8
%
)
9
(1
5
.0
%
)
1
(9
.1
%
)
O
th
e
r
5
9
(8
8
.1
%
)
1
0
(2
2
.7
%
)
0
9
(3
.9
%
)
3
(6
.4
%
)
2
(3
.3
%
)
0
K
P
S
<
7
0
6
(1
2
.8
%
)
1
(7
.7
%
)
1
(2
0
%
)
4
8
(3
1
.4
%
)
0
3
(1
0
.0
%
)
0
7
0
4
1
(8
7
.2
%
)
1
2
(9
2
.3
%
)
4
(8
0
%
)
1
0
5
(6
8
.6
%
)
2
4
(1
0
0
%
)
2
7
(9
0
.0
%
)
6
(1
0
0
%
)
R
a
d
io
/c
h
e
m
o
th
e
ra
p
y
Y
e
s
1
0
(1
6
.9
%
)
9
(2
0
.5
%
)
5
(5
0
%
)
1
3
2
(6
2
.3
%
)
2
1
(4
5
.7
%
)
3
5
(5
9
.3
%
)
6
(5
0
%
)
N
o
4
9
(8
3
.1
%
)
3
5
(7
9
.5
%
)
5
(5
0
%
)
8
0
(3
7
.7
%
)
2
5
(5
4
.3
%
)
2
4
(4
0
.7
%
)
6
(5
0
%
)
A
b
b
re
vi
a
ti
o
n
s:
K
P
S
,
K
a
rn
o
fs
k
y
P
e
rf
o
rm
a
n
ce
S
ta
tu
s.
1
1
Th
e
n
u
m
b
e
r
o
f
p
a
ti
e
n
ts
a
n
a
ly
se
d
fo
r
e
a
ch
cl
in
ic
a
l
fe
a
tu
re
m
a
y
d
if
fe
r
fr
o
m
th
e
to
ta
l
n
u
m
b
e
r
o
f
p
a
ti
e
n
ts
w
it
h
in
e
a
ch
h
is
to
lo
g
ic
a
l
su
b
ty
p
e
d
u
e
to
m
is
si
n
g
in
fo
rm
a
ti
o
n
.
T
um
or
M
ar
ke
rs
an
d
Si
gn
at
ur
es
Batista et al. 417
Int. J. Cancer: 139, 414–423 (2016) VC 2016 UICC
Ta
b
le
2
.
C
li
n
ic
o
p
a
th
o
lo
g
ic
a
l
fe
a
tu
re
s
o
f
G
B
M
a
cc
o
rd
in
g
to
TE
R
Tp
m
u
ta
ti
o
n
st
a
tu
s
E
n
ti
re
se
ri
e
s
P
o
rt
u
g
u
e
se
se
ri
e
s
B
ra
zi
li
a
n
se
ri
e
s
C
li
n
ic
a
l
fe
a
tu
re
s1
TE
R
Tp
m
u
t
p
a
ti
e
n
t
(n
5
1
4
1
)
TE
R
Tp
W
T
p
a
ti
e
n
ts
(n
5
7
0
)
p
va
lu
e
s
TE
R
Tp
m
u
t
p
a
ti
e
n
t
(n
5
8
5
)
TE
R
Tp
W
T
p
a
ti
e
n
ts
(n
5
4
3
)
p
va
lu
e
s
TE
R
Tp
m
u
t
p
a
ti
e
n
ts
(n
5
5
6
)
TE
R
Tp
W
T
p
a
ti
e
n
ts
(n
5
2
7
)
p
va
lu
e
s
G
e
n
d
e
r
p
5
0
.2
8
3
p
5
0
.4
8
3
p
5
0
.0
1
2
Fe
m
a
le
5
1
(3
7
.0
%
)
3
0
(4
4
.8
%
)
3
2
(3
9
.0
%
)
1
3
(3
2
.5
%
)
1
9
(3
3
.9
%
)
1
7
(6
3
.0
%
)
M
a
le
8
7
(6
3
.0
%
)
3
7
(5
5
.2
%
)
5
0
(6
1
.0
%
)
2
7
(6
7
.5
%
)
3
7
(6
6
.1
%
)
1
0
(3
7
.0
%
)
A
g
e
p
<
0
.0
0
1
p
5
0
.0
0
4
p
<
0
.0
0
1
M
e
a
n
(R
a
n
g
e
)
6
1
(2
5
–
8
2
)
5
0
(1
8
–
8
0
)
6
0
(4
1
–
7
9
)
5
1
(1
8
–
7
7
)
6
2
(2
5
–
8
2
)
4
7
(1
8
–
8
0
)
Tu
m
o
u
r
Lo
ca
ti
o
n
p
5
0
.0
4
4
p
5
0
.6
4
4
p
5
0
.0
0
7
Fr
o
n
ta
l
1
8
(1
3
.3
%
)
1
6
(2
4
.6
%
)
1
4
(1
7
.7
%
)
9
(2
3
.1
%
)
4
(7
.1
%
)
7
(2
6
.9
%
)
Te
m
p
o
ra
l
4
1
(3
0
.4
%
)
1
2
(1
8
.5
%
)
1
9
(2
4
.2
%
)
9
(2
3
.1
%
)
2
2
(3
9
.3
%
)
3
(1
1
.5
%
)
P
a
ri
e
ta
l
2
3
(1
7
.0
%
)
1
3
(2
0
.0
%
)
1
4
(1
7
.7
%
)
8
(2
0
.5
%
)
9
(1
6
.1
%
)
5
(1
9
.2
%
)
O
cc
ip
it
a
l
6
(4
.4
%
)
5
(7
.7
%
)
5
(6
.3
%
)
2
(5
.1
%
)
1
(1
.8
%
)
3
(1
1
.5
%
)
M
u
lt
ip
le
4
5
(3
3
.3
%
)
1
5
(2
3
.1
%
)
2
5
(3
1
.6
%
)
8
(2
0
.5
%
)
2
0
(3
5
.7
%
)
7
(2
6
.9
%
)
O
th
e
r
2
(1
.5
%
)
4
(6
.2
%
)
2
(2
.5
%
)
3
(7
.7
%
)
0
1
(3
.8
%
)
K
P
S
p
5
0
.5
5
2
p
5
0
.5
7
5
p
5
0
.6
2
1
<
7
0
2
8
(2
9
.8
%
)
1
4
(3
5
.0
%
)
1
6
(3
6
.4
%
)
9
(4
7
.4
%
)
1
2
(2
4
.0
%
)
5
(2
3
.8
%
)
7
0
6
6
(7
0
.2
%
)
2
6
(6
5
.0
%
)
2
8
(6
3
.6
%
)
1
0
(5
2
.6
%
)
3
8
(7
6
.0
%
)
1
6
(7
6
.2
%
)
R
a
d
./
C
h
.
th
e
ra
p
y
p
5
0
.3
9
5
p
5
0
.8
2
2
p
5
0
.6
2
3
Y
e
s
7
8
(6
1
.9
%
)
3
9
(6
8
.4
%
)
4
4
(6
2
.9
%
)
2
1
(6
7
.7
%
)
3
4
(6
0
.7
%
)
1
8
(6
9
.2
%
)
N
o
4
8
(3
8
.1
%
)
1
8
(3
1
.6
%
)
2
6
(3
7
.1
%
)
1
0
(3
2
.3
%
)
2
2
(3
9
.3
%
)
8
(3
0
.8
%
)
A
b
b
re
vi
a
ti
o
n
s:
K
P
S
,
K
a
rn
o
fs
k
y
P
e
rf
o
rm
a
n
ce
S
ta
tu
s;
TE
R
Tp
m
u
t,
TE
R
T
p
ro
m
o
te
r
m
u
ta
te
d
;
TE
R
Tp
W
T,
TE
R
T
p
ro
m
o
te
r
w
il
d
-t
yp
e
;
R
a
d
./
C
h
.t
h
e
ra
p
y,
R
a
d
io
o
r
C
h
e
m
o
th
e
ra
p
y;
B
o
ld
,
st
a
ti
st
ic
a
ll
y
si
g
n
ifi
ca
n
t.
1
Th
e
n
u
m
b
e
r
o
f
p
a
ti
e
n
ts
a
n
a
ly
se
d
fo
r
e
a
ch
cl
in
ic
a
l
fe
a
tu
re
m
a
y
d
if
fe
r
fr
o
m
th
e
to
ta
l
n
u
m
b
e
r
o
f
p
a
ti
e
n
ts
w
it
h
in
e
a
ch
TE
R
Tp
ca
te
g
o
ry
d
u
e
to
m
is
si
n
g
in
fo
rm
a
ti
o
n
.
T
um
or
M
ar
ke
rs
an
d
Si
gn
at
ur
es
418 TERTP mutations and SNP in GBM survival
Int. J. Cancer: 139, 414–423 (2016) VC 2016 UICC
mutations was signiﬁcantly associated with older age at diag-
nosis and different tumour location: GBM with TERTp muta-
tions were more frequently located in the temporal lobe,
while GBM without TERTp mutations were more evenly dis-
tributed, albeit being more frequently located in the frontal
lobe (Table 2). Following GBM stratiﬁcation according to
their origin (Portuguese or Brazilian), the signiﬁcant associa-
tion of TERTp mutations with older age at diagnosis was
retained in both groups, while the association with tumour
location was kept only in the Brazilian patients, with the
same trend observed in Portuguese patients (Table 2). Within
Brazilian patients, TERTp mutations were also associated
with male patients (Table 2).
Using Kaplan-Meier analysis, we observed that GBM
patients harbouring TERTp mutations had signiﬁcantly
shorter survival than GBM patients without TERTp muta-
tions (median 10.0 vs. 21.0 months; Log-rank test
p< 0.0001; Fig. 1a). No differences in survival were found
between patients with the c.2124:G>A mutation and
those with the c.2146:G>A mutation (Fig. 1a). The corre-
lation between TERTp mutations and worse survival was
preserved when Portuguese (median 13.0 vs. 21.0 months;
Log-rank test p5 0.008) and Brazilian (median 6.0 vs. 21.0
months; Log-rank test P5 0.01) patients were analysed sep-
arately (Supporting Information Figs. S1 and S2, respec-
tively). In Kaplan-Meier analysis, patients with a Karnofsky
Performance Status <70 (median 8.0 vs. 12.0 months; Log-
rank test p5 0.021) and patients aged 50 years (median
11.0 vs. 20.0 months; Log-rank test p5 0.001) were also
associated with signiﬁcantly shorter survival (Figs. 1 band
1c, respectively). The multivariate Cox regression models of
overall survival, using TERT mutational status, age at diag-
nosis and preoperative Karnofsky Performance Status (<70
vs. 70) as covariates, showed that TERTp mutations
remained signiﬁcantly associated with worse survival (HR
1.851, 95% CI 1.078–3.204, p5 0.027; Table 3), while age
at diagnosis (computed as a continuous variable) showed a
borderline value (HR 1.019, 95% CI 1.000–1.039, p5 0.048;
Table 3).
TERTp mutations in oligodendrogliomas
TERTp mutations were also frequently detected in oligoden-
drogliomas grade II (25/54; 46.3%) and III (34/66; 51.5%).
Similar to what we observed for GBM, TERTp mutations
were signiﬁcantly associated with older age at diagnosis, both
in grade II and III oligodendrogliomas (Supporting Informa-
tion Table S5). In grade II patients, the presence of TERTp
mutations was signiﬁcantly associated with male patients, a
ﬁnding not observed for grade III patients (Supporting Infor-
mation Table S5). No association was found between TERTp
mutations and tumour location in grade II and III oligoden-
drogliomas (Supporting Information Table S5). In contrast to
Figure 1. Overall survival of GBM patients according to TERTp mutation status (a), Karnofsky Performance Status (KPS; b) and age at diag-
nosis (c).
Table 3. Univariate and multivariate analysis of prognostic factors for overall survival in GBM patients
Univariate analysis Multivariate analysis
Clinical features p values HR 95% CI p values HR 95% CI
KPS 0.027 1.581 1.054–2.371 0.122 1.435 0.908–2.266
Age (continuous) 0.000 1.026 1.013–1.039 0.048 1.019 1.000–1.039
TERTp mutation 0.000 2.136 1.428–3.193 0.027 1.851 1.078–3.204
Abbreviations: KPS: Karnofsky performance status; HR: hazard ratio; CI: confidence interval; Bold: statistically significant.
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the results in GBM patients, the presence of TERTp muta-
tions was not associated with worse survival in grade II or
grade III oligodendroglioma patients (Supporting Information
Figs. S3 and S4, respectively).
TERTp mutations in oligoastrocytomas
We detected the presence of TERTp mutations in 40.0%
(4/10) of oligoastrocytomas. The clinicopathological features
did not differ between patients with and without TERTp
mutations, although the sample was too small to allow deﬁ-
nite conclusions (Supporting Information Table S4).
rs2853669 TERTp SNP in GBM
In light of previous reports showing that the rs2853669
2245:A>G SNP in the TERTp region modiﬁes the prognos-
tic value of TERTp mutations, we assessed the clinical value
of TERTp mutations in GBM patients according to their
rs2853669 background. We ﬁrst screened the 2245:A>G
polymorphism in GBM patients and found that the G allele
was present in 47% of GBM patients (77/164) and that the
most common genotype was A/A (87/164; 53.0%), followed
by A/G (61/164; 37.2%) and G/G (16/164; 9.8%) genotypes
(Supporting Information Table S6). The genotype frequencies
were similar in Portuguese and Brazilian series (Supporting
Information Table S6). Kaplan-Meier analysis in GBM
patients according to their rs2853669 background showed
that the poor prognosis conferred by TERTp mutations was
conﬁned to patients without the G allele (median 8.0 vs. 35.0
months; Log-rank test p< 0.0001; Fig. 2a), whereas in
patients carrying the G allele TERTp mutations were not sig-
niﬁcantly associated with worse prognosis (median 10.0 vs.
14.0 months; Log-rank test p5 0.923; Fig. 2b). Likewise, a
Karnofsky Performance Status <70 (median 8.0 vs. 12.0
months; Log-rank test p5 0.021) and an age at diagnosis
50 years (median 11.0 vs. 20.0 months; Log-rank test
p5 0.001) were signiﬁcantly associated with shorter survival
only in patients without the G allele (Supporting Information
Figs. S5A and S6A, respectively). In the multivariate Cox
regression models of overall survival (using TERT mutational
status, age at diagnosis and preoperative Karnofsky Perform-
ance Status as covariates), restricted to patients without the
G allele, only age at diagnosis remained signiﬁcantly associ-
ated with shorter survival in multivariate analysis (Table 4).
The presence of the G allele by itself was not associated with
age, gender, tumour location or TERTp mutation (data not
shown). Furthermore, the overall survival of GBM patients
was identical when we compared patients carrying the G
allele vs. those without the G allele, or when we compared
patients carrying the AA, AG and GG genotypes (Supporting
Information Figs. S7 and S8, respectively).
Figure 2. Overall survival according to TERTp mutation in GBM patients carrying the rs2853669 AA genotype (a) or carrying the rs2853669
GG or AG genotypes (G carriers; b).
Table 4. Univariate and multivariate analysis of prognostic factors for overall survival in GBM patients without the rs2853669 G allele
Univariate analysis Multivariate analysis
Clinical features p values HR 95% CI p values HR 95% CI
KPS 0.031 2.079 1.070–4.041 0.312 1.435 0.712–2.889
Age (continuous) 0.000 1.061 1.033–1.090 0.001 1.060 1.025–1.096
TERTp mutation 0.000 3.816 1.806–8.063 0.328 1.455 0.686–3.083
Abbreviations: KPS: Karnofsky performance status; HR: hazard ratio; CI: confidence interval; Bold: statistically significant.
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Discussion
The ﬁnding that telomerase is reactivated in the majority of
human cancers denotes that it plays a crucial role in tumour
development and/or progression. The identiﬁcation of TERTp
mutations has provided a genetic cause for telomerase reacti-
vation in a subset of human cancers, namely in gliomas
where TERTp mutations are particularly frequent. Further-
more, TERTp mutations were associated with increased TERT
mRNA expression in gliomas9,26 and also with decreased
telomere length,27 thus supporting the functional relevance of
such mutations in cancer. Interestingly, Chiba et al.28 showed
that neural precursor cells and neurons, engineered to carry
cancer-associated TERTp mutations, failed to repress TERT
transcription upon induction of differentiation and showed
robust telomerase activity, suggesting that TERTp mutations
are sufﬁcient to overcome the proliferative barrier imposed
by telomere shortening, thus promoting immortalization.
In this study we conﬁrmed that the highest frequency of
TERTp mutations is detected in GBM, followed by oligoden-
droglial tumours, while low grade astrocytic tumours exhib-
ited the lowest frequency of TERTp mutations. The TERTp
mutation frequency detected in GBM from our series (66.9%)
is lower than the one found in several studies,10,16,21,29 while
comparable to other series17,24,30 and higher that some stud-
ies.18,20,31 The lower percentage of TERTp mutations here
reported could be related with the fact that we did not sepa-
rate primary from secondary GBM; since secondary GBM
show a signiﬁcantly lower percentage of TERTp mutations,18
this could hinder (and lower) the overall percentage of
TERTp in GBM. The lower frequency of TERTp mutations in
grade I to grade III astrocytomas may be explained by their
lower malignancy grade or, alternatively, by the existence of
mechanisms such as ALT that provide telomere maintenance.
Supporting the latter hypothesis, ATRX mutations that are
able to trigger ALT, have been reported in low-grade
astrocytomas.15,32
Interestingly, we detected TERTp mutations in four out of
55 (9.1%) pilocytic astrocytomas, which are best known for
showing molecular alterations in the MAPK pathway.33–35 To
our knowledge, this has not been previously reported in the
literature, although most studies on this subject either do not
present data regarding pilocytic astrocytomas, or have very few
screened cases, with the exception of the study by Koelsche
et al.,20 who did not ﬁnd TERTp mutations among 111 pilo-
cytic astrocytomas. The four cases where we detected TERTp
mutations (two with the c.2124:G>A and two other with the
c.2146:G>A) did not present any particular features regard-
ing age, gender or disease outcome; nevertheless, our ﬁndings
warrant further studies in order to fully understand the rele-
vance of TERTp mutations in pilocytic astrocytomas.
No major differences were found between Portuguese and
Brazilian patients, an observation that reinforces the rele-
vance of the results obtained in the present study, independ-
ently of patient ethnic background.
Our results show that TERTp mutations are a major prog-
nostic factor for shorter survival in GBM patients, independ-
ently of other known clinical prognostic factors, such as
older age at diagnosis and poor Karnofsky Performance Sta-
tus. These ﬁndings are in accordance with previous reports
showing that TERTp mutations are an independent prognos-
tic factor in GBM and in other tumour types.10,21,26,36 Our
results should, however, be interpreted with caution, as we
were not able to assess the prognostic value of IDH muta-
tions in GBM, due to the low number of mutated cases (6
out of 211) and to lack of clinical information. Heidenreich
et al.27 showed that the group of glioma patients with the
combined presence of IDH and TERTp mutations had the
best overall survival, while the worst overall survival was
observed in patients carrying TERTp mutations only. Since
IDH mutations are known to be major prognostic indicators
in low- and high-grade gliomas,21,30,37 our results require val-
idation in larger datasets, with thorough genetic and clinical
information, that provide statistical power to assess the com-
bined prognostic signiﬁcance of TERTp and IDH mutations.
Nonoguchi et al.18 observed that only the TERTp
c.2124:G>A mutation was predictive of shorter survival in
GBM patients; this could be related with the ﬁnding that the
TERTp c.2124:G>A leads to higher transcriptional activity
of the TERT promoter when compared with the
c.2146:G>A mutation,38 although both mutations generate
the same putative ETS-binding motif. This apparent discrep-
ancy suggests a strong positional effect between the location
of the ETS mutation and the core transcription initiation
machinery, as suggested by Chiba et al.28 Our results, how-
ever, did not replicate those of Nonoguchi et al.,18 as we did
not ﬁnd differences in overall survival when comparing the
c.2124:G>A with the c.2146:G>A mutation.
Our study also demonstrates that the prognostic value of
TERTp mutations depends on the status of the rs2853669
2245A>G SNP. In a univariate analysis, the poor prognosis
conferred by TERTp mutations seems to occur only in GBM
patients that do not carry the G allele in position 2245,
while in those carrying the G allele in homozygosity or heter-
ozygosity, TERTp mutations do not affect overall survival.
This is in accordance with recent reports in GBM patients, in
which it was also demonstrated a major inﬂuence of the
rs2853669 SNP on the prognostic effect of TERTp muta-
tions.23,24,39 The modiﬁer effect of the rs2853669 SNP may
be related with a lower telomerase activity and TERT expres-
sion conferred by the G allele,22 thereby blunting the effect of
TERTp mutations. When we further performed a multivariate
analysis, considering also the clinical variable age and Kar-
nofsky Performance Status, we did not conﬁrm this ﬁnding,
probably due to the lack of statistical power and also to the
absence of important clinical parameters, such as tumor
resection and patient therapy and molecular features such as
IDH mutations and 1p/19q loss. If conﬁrmed in additional
studies, the status of the rs2853669 SNP would be an impor-
tant aspect to consider when evaluating TERTp mutations;
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indeed, this SNP may explain some discrepancies observed in
the literature regarding the prognostic value of TERTp muta-
tions in GBM. Given the prognostic relevance of IDH muta-
tions, it will also be crucial to understand how the rs2853669
alleles may modulate GBM outcome, taking into considera-
tion not only TERTp mutations, but also IDH mutations and
1p/19q losses.
In line with previous reports, the presence of TERTp
mutations was consistently associated with older age at diag-
nosis across gliomas with different histotypes and grades,
with the exception of oligoastrocytomas. Although this might
be expected, taking into consideration that older age is also
associated with poor prognosis in GBM patients, the fact that
TERTp mutations remain as poor prognostic factors in the
multivariate analysis implies a role for TERTp mutations
both in early and later stages of glioma development.
To our knowledge, we report for the ﬁrst time that GBM
location is signiﬁcantly different when comparing TERTp
mutant with TERTp WT GBM, namely an increased fre-
quency of temporal lobe tumours in TERTp mutant GBM. In
two reports that analyse tumour location according to TERTp
mutation status, no signiﬁcant differences were uncovered;
however, the results of Chen et al. also show a trend for tem-
poral lobe location in TERTp mutant GBM.38
In conclusion, we present evidence that TERTp mutations
are a major indicator of poor survival in GBM, independently
from other risk factors such as age and Karnofsky Perform-
ance Status. In addition, the effect promoted by TERTp
mutations may be modiﬁed by a common SNP in the TERT
promoter region, but studies in larger series are necessary to
fully elucidate this ﬁnding.
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